Jade Biosciences (JBIO) investor relations material

Financial update and cash runway

• Secured $135 million in private financing, extending operational runway into the first half of 2028 and supporting advancement of multiple pipeline programs.

• Funding supports ongoing and planned clinical development activities for JADE-101, JADE-201, and JADE-003, with exclusive licenses for the first two and an option for the third.

• Interim data for JADE-101 expected in the first half of 2026; JADE-003 first-in-human trial planned for the first half of 2027.

• Building a team with deep expertise in drug development, regulatory strategy, and commercial execution.

Lead and pipeline programs

• JADE-101, a selective APRIL inhibitor, is in phase one for IgA nephropathy, targeting a large unmet need and multibillion-dollar market.

• JADE-101 aims for best-in-class efficacy with subcutaneous dosing every eight weeks, seeking to demonstrate full APRIL suppression and disease modification.

• JADE-201, a half-life extended, afucosylated anti-BAFF-R monoclonal antibody, is the primary focus, with first-in-human studies in rheumatoid arthritis planned for the first half of 2026.

• JADE-003, an undisclosed antibody program, is expected to enter human studies in 2027.

JADE201 profile and differentiation

• JADE-201 is engineered for dual action: enhanced B cell cytotoxicity and BAFF-R signaling blockade, aiming for deeper, more durable B cell depletion and less frequent dosing.

• Demonstrates enhanced ADCC, broad BAFF-R binding, and half-life extension for less frequent dosing.

• Preclinical studies show robust ADCC, sustained B cell depletion, and a twofold increase in half-life over ianalumab.

• Dual mechanism may better target tissue-resident B cells and block compensatory BAFF upregulation, addressing limitations of first-generation B cell depleters.

• JADE-201 spares early-stage, nonpathogenic B cells, differentiating it from CD19, CD20, and CAR-T approaches.